Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tryp Therapeutics Inc (OP: TRYPF )

0.0570 -0.0050 (-8.06%)
Streaming Delayed Price Updated: 3:16 PM EDT, Mar 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 97,567
Open 0.0620
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0620
Today's Range 0.0500 - 0.0620
52wk Range 0.0400 - 0.1762
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Psyched: NY Discusses Regulations, MDMA For PTSD Aims For Legalization, Shrooms For Eating Disorders & More
Guess Which East Coast State Is Now Discussing Legalizing Psychedelics? Decriminalizing psychedelics is one thing, but fully legalizing them is another. That's currently a measure before New York's... 
Via Benzinga
Treating Binge Eating Disorder With Magic Mushrooms: Phase 2 Clinical Trial Gets Thumbs Up
Clinical-stage psychedelics biotech Tryp Therapeutics, Inc. 
Via Benzinga

Performance

YTD
-36.10%
-36.10%
1 Month
-22.87%
-22.87%
3 Month
-52.50%
-52.50%
6 Month
-46.98%
-46.98%
1 Year
-43.23%
-43.23%

More News

Read More
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Interim Results, Encouraging Trends for Phase II STOP Trial
Via Investor Brand Network
Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy
Via ACCESSWIRE
Business & Academia Join Forces To Study Magic Mushroom Therapy For IBS Patients
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), MGH to Collaborate in Clinical Study Investigating Psilocybin-Assisted Psychotherapy for IBS Patients
Via Investor Brand Network
Tryp Therapeutics and Massachusetts General Hospital Sign Letter of Intent for Clinical Study Investigating the Use of Psilocybin-Assisted Psychotherapy for the Treatment of Patients Suffering From Irritable Bowel Syndrome (IBS)
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at Biotech Showcase
Via Investor Brand Network
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases FY 2022 Financial, Corporate Report
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
From Virtual Investor Conferences
Via Globe NewsWire
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Participate in Upcoming Online Investor Conference
Via Investor Brand Network
Tryp Therapeutics to Webcast Live at VirtualInvestorConferences.com on Thursday, December 15
From Virtual Investor Conferences
Via Globe NewsWire
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Poster Presentations for Upcoming SfN Conference
Via Investor Brand Network
This Psychedelics Company Is Patenting Its Psilocin And Psilocybin Delivery Route
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Notes WIPO Publication of International PCT Patent Application
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Is Psilocybin Therapy A Potential Treatment For Fibromyalgia & Binge Eating Disorder?
Via Benzinga
PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Methodical Expansion of Its IP Portfolio
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Veteran Finance Exec as CFO
Via Investor Brand Network
Psychedelics Companies Share Corporate Updates: Numinus, Delix, Tryp And Small Pharma
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with IMS Investor Relations for Consulting, Communications and Outreach Services
Via Investor Brand Network
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Expands IP Portfolio with New Provisional Patent Application
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Health Care and Biotech Expert as New Chief Operating Officer
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Via Benzinga
Clinical Trials Of Psilocybin Treatment For Overeating Disorder Are Ready, Here's What Results Show So Far
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Results from Phase II Binge Eating Disorder Clinical Trial
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.